Author: admin

BOND and Lab21 collaborate to develop new molecular testing system BD MAX Aspergillus test

|

BD and Lab21 collaborate to develop new molecular testing system BD MAX Aspergillus test ™

BALTIMORE and CAMBRIDGE, England, August 3, 2011/PRNewswire /-

-the agreement involves a planned action leading to the menu of content-rich systems tests

BD Diagnostics, a segment of BD (Becton) global medical technology company(, Dickinson and Company) (NYSE: BDX), and Lab21, a world leader in personal health, have today announced a collaboration to develop a molecular diagnosis of last generation test to detect fungi Aspergillus, which pose a threat to life, using the fully automated molecular test BD MAX ™.

“ Potential to detect Aspergillus in blood using real-time Polymerase chain reaction is a topic of great interest for doctors, as it offers strategies for diagnosis and control more sensitive and accurate for final and primary detection of the aspergillosis ”, said Graham Mullis, Managing Director of Lab21.

Infections caused by Aspergillus is a major cause of death by infection in immunocompromised patients, and an estimated 10 million people in the world at risk each year. Studies have shown that the diagnosis of Aspergillus infection followed by an anti-fungal treatment 10 days after infection reduces mortality, from 90% to 40% – emphasizing the need for rapid and acute tests. Real-time Polymerase chain reaction could offer important advantages in the sensitivity and specificity to the current techniques of cultivation.

“ This agreement with Lab21 has been designed in order to add an innovative test to the menu of test growing system DB MAX to help doctors and professionals of the laboratories with rapid and accurate information on which to base treatment decisions important molecular ”, said Tom pollen, general director of BD Diagnostics – Diagnostic Systems. “ To collaborate with the best developers in his class of in vitro diagnostics, such as Lab21, our goal is to get the system DB MAX to be an indispensable tool in clinical laboratories, providing a menu of test growing in a fully automated platform ”.

According to pollen, BD plans carry new trials to MAX bond system in a wide range of disease categories. With this announcement, it now has more than 14 trials in the range of the menu of featured content of the system DB MAX. In combination with the ability to open, standardized workflow and full automation, the BD MAX system will enable laboratories to consolidate and standardize their molecular test to build programs that meet the current and future needs.

About BD

BD, a major global company in the medical technology develops, manufactures and sells medical devices, instrument systems and reagents. The company is dedicated to improving the health of people around the world. Bond focuses on improving therapies of drugs, improving the quality and speed of diagnosis of infectious diseases, and the advancement of research and discovery of new drugs and vaccines. The capacities of BD are instrumental to combat some of the most pressing diseases of the world. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs nearly 29,000 people in more than 50 countries around the world. The company provides its services to health institutions, researchers of the science of life, clinical laboratories, industry and public in general. If you would like more information please visit http://www.bd.com.

About Lab21

Lab21 is a global leader in personalized treatments. It provides products for diagnosis and services that support the control of the blood banks, medical diagnostics and drug discovery. Lab21 customers include international suppliers of health treatments, Diagnostics and pharmaceutical companies. Lab21 products division manufactures kits for immunological diagnosis and reagents that are distributed in international way and focus on infectious diseases for blood banks and clinical markets. Clinical Lab21 services operations include a growing test portfolio, providing company diagnosis and molecular testing of high-tech. Lab21 corporate offices are located in Cambridge, United Kingdom, and South Carolina, United States, and their manufacturing GMP site is in Cambridge, as well as with other plants for the production in Newmarket, Camberley and Bridport. Website: http://www.lab21.com

Read More

Presented at the World Congress of menopause last studies of hormonal treatments for vaginal atrophy.

|

Presented at the World Congress of menopause the latest studies on hormone to atrophy treatments vaginal.

Рa million and half of women in Spain suffer from symptoms associated with vaginal atrophy in its hipoestrog̩nica phase, but only one in four women consultation with your health care provider

-women complain before hot flushes and sweating that of vaginal dryness which will worsen with age if it is not treated

-vaginal atrophy affects half of all women in menopause and influences of determining how sexual functionality and their quality of life

Rome, 2011-June every three years, the international Menopause Society organizes a World Congress on menopause in trying to take stock of the latest studies and data published in the scientific literature. The 13th World Congress on menopause, held this year in Rome has hosted gynecologists experts on pathogenesis and treatment of premature menopause and osteoporosis as well as the impact of hormonal cancer, cardiovascular disease or osteoporosis treatment, the effects of menopause on the mood and the central nervous system, among other topics. Spanish participants highlighted the presence of Dr. Sanchez Borrego, President of the Spanish Association for the study of the menopause-EMEA. Dr. Sanchez Borrego has valued the important speeches made by all the professionals from Spain, most notably the submission of the studies presented by doctors Antonio Cano, Chief of the service of Gynecology and obstetrics at the Hospital Universitario Dr. Peset of Valencia and Juan Luis Delgado, attached to the service of gynaecology and obstetrics of the Hospital Universitario Virgen of the Arixaca of Murciaon the estriol formulated gel administered vaginally.

Latest data on vaginal atrophy

Vaginal atrophy is the medical term that refers to the thinning of the vaginal wall that occurs during menopause. Vaginal atrophy has undoubtedly been one of the protagonists in the World Congress of menopause as a pathology of high prevalence in women at menopause. It is estimated that approximately between 40-60% of women in menopause suffer local symptoms associated with vaginal atrophy that occurs as a result of the progressive fall of estrogen, something characteristic of this stage of the life of the woman.

A series of symptoms whose effects are very subjective depending on each woman appear in women in menopause. Although vasomotor symptoms such as hot flashes and night sweats are resolved in the majority of cases spontaneously with the passage of time (2-3 years), the symptoms associated with atrophy of the urogenital tract, and vagina worsen progressively, increasing problems and consequently the quality of life, for this reason these symptoms – such as vaginal dryness – reaching the second complaint of women in this stage of life.

Some data provided by other countries indicate that approximately 5% of all women attending a gynecological visit concern dyspareunia (pain with intercourse) in relation to vaginal dryness, a percentage that is three or four times higher in women during menopause and is known increases with the age of the woman. In general there are several discomfort associated with the field urogenital, such as incontinence or trigonitis (inflammation of the bladder triangle that forms the base of the bladder). Vaginal dryness, according to the VIVA survey is currently under the Spanish society of Gynecology and obstetrics is the vaginal symptoms most frequently referred to, is associated with dyspareunia and dysuria (pain when urinating) are problems that frequently cite the patients with menopause is defined as “ not symptomatic ” and thereforelittle treated, but that actually punishes harshly the life of relationship and affects their quality of life.

However only 1 of every 4 query for this reason despite the fact that these symptoms are usually progressive and worsen in the absence of treatment, in fact narrowed epithelium causes with the rubbing of sexual relations occurring pain accompanied by bleeding for the treatment of choice is to manage an estrogen level topical (local action and that) (no passes into the blood). “ Is important to clarify that these oestrogens have nothing to do with the controversy of estrogen at menopause, known hormone replacement therapy ” specifies Dr. Sanchez Borrego, President of the EMEA.

Effective and safe treatments

Local treatments include vaginal moisturizers which can partly alleviate these annoyances but not reverse the atróficos changes associated with menopause for what would be necessary to the use of the treatment of choice with estrogen. To treat vaginal dryness, topical hormonal treatments of estriol (estrogen weaker few produces women), it is recommended that to be an effective ingredient for local use reduces the overall absorption throughout the body and thereby consequential adverse events incidence.

The use of dose ever-lower and different from the oral routes of administration are the new perspective on the treatment of the symptoms of menopause, which is intended to increase the beneficial effects while reducing side effects.

More information about the EMEA

The EMEA is the scientific society of reference in the care of the peri- and postmenopausal women. This association aims to educate women to ask more on climacteric symptoms and professionals to make them more proactive to the complaints of his patients, in this way can reverse some of the symptoms that are most troublesome for women in menopause. Its motto in this 2011 on the basis of the international day of menopause was the of “ Vaginal health ”.

Read More

The self control of capillary glucose in type 2 diabetes diagnosis favours the recovery of the beta cell.

|

self-monitoring of blood capillary in type 2 diabetes diagnosis favours the recovery of cell beta.


-the San Carlos study shows that self-monitoring of capillary glucose accompanied by a curriculum significantly improves glycaemic control in patients with diabetes type 2 not treated with insulin.

– has been in 161 consecutive with Diabetes patients type 2 (DM2) diagnosed between 2006 and 2007 with HbA1c < 8% and ≪ 6 months from diagnosis

Madrid, June 2011.- according to data from the National Institute of statistics (INE), it is estimated that the number of adults with diabetes around the world will rise from 135 million in the year 1995 to 300 million by the year 2025. About 95% of patients who suffer from this disease they suffer from type 2 diabetes. These figures make particularly relevant the study carried out by Dr. a. Calle Pascual, and introduced the enormously June 17 in the ’ days of latest developments in Diabesidad for AP´, whose main objective was the evaluate the benefits of managing the glycemic control through self-monitoring of capillary glucose, with the use only of hemoglobin glycosylated.


key: self-monitoring of glucose capillary.

the main objective of the ’ Studio San Carlos. Benefits of self-monitoring in Diabetes type 2 of recent diagnóstico´ is the transmit to “ there is a recovery of the cell beta based on the improvement of the levels of insulin and the estimation of insulin resistance as measured by HOMA-IR, without specifying other than metformin drug ”. However, Dr. Street – author of this – explains that: “ confirm a total healing would be excessive. Right thing to would be to talk a regression of diabetes and the obtaining of blood glucose values similar to persons who do not have this condition, that, although there is a return to stages prior to the hiperglucémica phase, probably other markers could remain altered ”.

the analysed sample comprises a total of 161 consecutive DM2 patients diagnosed between 2006 and 2007 with HbA1c < 8% and ≪ 6 months from diagnosis; still included 99 of them in a group conducting self-analysis structured capillary glucose and 62 in the group control.

defined profile of self-analysis was 6 points before and two hours after the breakfast, lunch and dinner, in an attempt to reach optimum levels throughout the day. After a thorough follow-up found that structured self-analysis group achieved a higher rate of regression defined HbA1c < 6% and reference defined by HbA1c 6 to 6.4 per cent than the control group.

This shows that when using the self-monitoring of capillary glucose in patients properly “ educated ”, manages to achieve the control objectives more effectively using only the hemoglobin glycosylated.

the study provides evidence consistent on the value of SMBG structured blood capillary as an educational tool for the patient and as a tool to optimize the treatment of diabetes by the professional, allowing changes active and targeted therapy.


peculiarities of the patient DM2.

as opposed to other types of diabetes, not all patients with DM2 are forced to take medication or require insulin injections; much control your blood sugar levels simply meal planning and exercise. According to Dr. Street: “ several studies have shown an intervention based on lifestyle changes can prevent more than 50% of cases of diabetes type 2 in patients at risk for developing. Physical exercise is a crucial parameter; at least 30 minutes a day are essential for success ”.


the role of the tools for management of blood sugar.

the great technological advances of recent decades has provided tools to help in the process of registration, interpretation and transmission of data of capillary glycemia, providing support in the process of care to the diabetic patient.

according to the DRA. Pérez Ferre, who intervened ’ new technologies applied to the monitoring of the diabetes´, “ these programs of management of blood glucose data or information on glycaemia managers have emerged to help extract the most out of the automonotorización of capillary glycemia, constituting a valuable and motivating educational element to the patient, learn to identify what they see, knowing where are their difficulties and learning how to set goals ”.

occasionally there is some resistance from health professionals in the use of these computer systems because they involve a learning process and a time of prior commitment. However, they offer a wide range of possibilities for the treatment of the patient, with very specific data, structured in tables and graphs. In addition, electronic notebooks allow information traveling over the Internet, making possible the integration of telemedicine.



Read More

Biocruces scientists identified 1,500 genes altered by the celiac gluten intolerance.

|

Biocruces scientists identified 1,500 genes altered by the intolerance to gluten gluten-free.

research genetics in the BioCruces Institute.


– the researchers of the Institute are looking for a therapy that reduces the effects of gluten in patients and that might be available in cases of exceptional, accidental intake or volunteer.

-BioCruces team has identified a gene whose modulation is able to return to normal function of the biological route.-

“ once proved the concept, are looking at the magnitude of the effect of the modulation of the biological route in control processes such as inflammation and cellular injury ” explains Dr. José Ramón Bilbao, responsible of the laboratory of Immunogenetics of BioCruces and leader of this research


Bilbao, June of 2011- research carried out by the BioCruces Institute in the field of celiac disease is bearing fruit. Vizcaíno Center scientists have succeeded in detecting more than 1500 genes altered by the intolerance to gluten for celiac patients. This project, led by the head of the laboratory of Immunogenetics of the Institute, Dr. José Ramón Bilbao, along with Leticia Plaza and Nora Fernandez, and whose main clinical researcher is Dr. Juan Carlos Vitoria, is intended to reduce the toxic effects of gluten in the gluten-free, modulating the intensity of inflammation in the gut, so reduction in symptoms associated with the ingestion of gluten.

“ is to find a complementary therapy that may be available to celíacas for cases of exceptional gluten ingestion (accidental or voluntary) ”, explains Dr. Bilbao. Therefore scientists departed that base “ there must be many genes altered by exposure to gluten, and we are dealing with your ID at the beginning of this project ”.

using expression microarrays, analysed all the genes in the genome to detect changes in function which occurred by effect of gluten, comparing biopsy of celiac patients taken to the diagnosis, they were taken after two years of diet free of gluten. “ thus identified more than 1,500 altered genes, which could group in biological processes more complex (growth and cell death, communication between cells, etc.) potentially relevant to the development of the disease ”, points Bilbao.

in one of these biological pathways, the BioCruces team has managed to identify a gene whose modulation is able to return to normal function of the biological route. The group is currently doing a more comprehensive study of all of the altered biological path and its consequences, testing the effects of modulation in exposures to different amounts and times of incubation of gluten. To do this, perform experiments with leftover debris from biopsies of celiac people and crops of cellular models of intestino delgado.

“ could say that once proved the concept, we are looking at the magnitude of the effect of the modulation of the biological route in control processes such as inflammation and cellular injury ”, outlines the leader of the research, which adds that “ is a slow process ”. In fact, BioCruces experts do not expect to test therapies on animals for two years, then start to test trials in people.



Read More

Orafti (R) Synergy1 reduces energy intake in people with overweight and obesity.

|

Orafti (R) Synergy1 reduces the energy intake in people with overweight and obesity.

Spain, 2011-June the results of a new study led by Professor Rob Welch (University of Ulster, the North Ireland) show that BENEO Orafti (R) Synergy1 leads to a lower energy intake in adults with overweight and obesity. The study recently presented for the first time in the 18 th European Congress on obesity (ECO), which was held in Istanbul from 25 to 28 May 2011.

The study of speech randomised, double blind, placebo controlled and Crusader (1) included 36 men and women volunteers with overweight or obesity, received 6 grams of Orafti ® Synergy1 (OLIGOFRUCTOSE-enriched inulin) a day in the breakfast and lunch in the form of supplement dissolved in a drink or a placebo (MALTODEXTRIN) for three weeks. The objective of the study was to determine the effects of Synergy1 on the energy intake as well as the sensation of appetite in the participants. While the energy intake was determined at the beginning and the end of each phase of treatment, appetite ratings were assessed through visual analogue scales (EVA).

Demonstrated that intake Synergy1 resulted in an energy intake significantly lower in all the subject (- 3.6%), and when they stratified by sex, this result was even more obvious in women. Anke Sentko, Vice President Regulatory Affairs and Nutrition Communication, BENEO-Institute (Vice-Chairman of the Legal Department and nutrition communication), says: ’ we are happy to see that the well-designed intervention study conducted on human beings by Professor Welch and his team has shown that Synergy1 ® Orafti’s BENEO has the effect of reducing the energy contribution of participants. ” This shows that small changes in the daily feed will be added and will eventually make the difference, because they are much easier to accept and integrate into the daily life of the mundo.»

research in animals to the evidence in humans: the understanding of the effects of Prebiotics on food intake and weight.

In addition to the recent results achieved by Welch, other recent findings make a beneficial role of Prebiotics inulin and oligofructose in relation to the regulation of energy homeostasis, in addition to the well-known positive effects on the intestinal microbiota.

Research in this field has begun studies in animals. Numerous findings have shown that the inclusion of the BENEO Prebiotics in rodents feeding reduces its energy intake, which is accompanied by a weight lower and less development of body fat in comparison with animals who receive regular food. Such effects were demonstrated in models of thinness, but also of genetic or food-induced obesity. In animals, these effects have been observed at the same time modulation of hormones involved in the regulation of appetite, such as GLP-1 concentrations rise.

Healthy adults, had previously shown that intake of 8 grams of Orafti ® Synergy1 twice a day resulted in a lower energy intake (6% reduction) and a minor sensation of hunger compared to placebo (MALTODEXTRIN). Synergy1 increased even more significantly the peptide concentrations similar to glucagon 1 (GLP-1) and peptide YY (PYY), two peptide that is secreted in the lower portion of the gastrointestinal tract and are involved in the signaling pathway of satiety to the brain (2).

In addition, a study carried out with supplementation of OLIGOFRUCTOSE (Orafti ® P95) in a higher dose (3 x 7 g/day) in healthy adults with overweight or obesity during a period of 12 weeks resulted in a lower energy intake and loss of body weight (about 1 kg)(, mainly fat loss). This study also demonstrated effects on blood concentrations of appetite regulatory hormones: a lower postmeal ghrelin response and a greater response of PYY on subjects that consumed oligrofructosa (3).

Energy intake: a conclusive finding

Environment «obesogénico» in which we live, which is characterized by a few tasty food readily available is probably one of the main causes for the dizzying levels of obesity factors, it has as a result an imbalance in the long term between the input and energy expenditure. ’ If you look at all of studies in humans, it is clear that the energy input is a key parameter that changes systematically with the intake of Orafti ® Synergy1, both in healthy volunteers with overweight and obesity, partnering in this way Synergy1 to healthy diets for weight control ’’,’ resume Anke Sentko.

Orafti ® Synergy1 is an OLIGOFRUCTOSE-enriched inulin and a renowned prebiotic. His carefully selected distribution of chain lengths allows a constant fermentation over large areas of the intestine, which presumably include most proximal and distal parts. Orafti ® Synergy1 contributes to the maintenance of a healthy composition of intestinal microbiota, as well as the reduction of the energy intake and maintaining energy balance.

About beneo

BENEO-Institute is an organization that brings together the experience of BENEO nutrition science, nutrition communications and legal affairs teams. It acts as advisory body for customers and partners, and covers issues ranging from the approval of ingredients, through physiological effects and nutritional composition, labelling and communication. Key nutritional issues that form the basis of the work of the BENEO-Institute include the weight control, digestive health, bone health, physical and mental effects of a diet of low performance load glucémica in the context of healthy diet and the prevention of diseases, as well as dental health.

BENEO-Institute facilitates access to the research and the latest scientific knowledge on all nutritional and legal issues associated with the BENEO ingredients. Guidance to clients and partners of BENEO corroborated on some of the issues of fundamental importance in the industry of food

BENEO is a division of Südzucker group, gives employment to almost 900 people and possesses of production units in Belgium, Chile, Germany and Italy.


–
referencia:
(1) MT McCann, Livingstone MBE, Wallace JMW, Gallagher AM, Welch RW. OLIGOFRUCTOSE-enriched inulin supplements reduce energy intake in men and women with overweight and obesity. Obesity Reviews 12 (Suppl. 1) (2011) 63-279

(2) Cani PD, others E, Dewulf EM Sohet FM, Pachikian BD, Naslain (d), Backer of F, Neyrinck AM & Delzenne NM (2009). The fermentation of Prebiotics on intestinal microbiota increases the production of peptides intestinal saciógenos and incretina type with consequences for the sensation of appetite and the response of postmeal glucose. American Journal of Clinical Nutrition 90: 1236-1243.

(3) Parnell JA & Reimer RA (2009). Weight loss during OLIGOFRUCTOSE supplements is associated with a decrease of the ghrelin and PYY the increased in adults with overweight and obesity. American Journal of Clinical Nutrition 89: 1751-1759.

Read More

Surah Al-Rehman – The Ultimate Free Remedy for Incurable Diseases

(By Listening Only- 20 Minutes Only)

Kindly download the Surah “AL-REHMAN” (recited by Qari Abdul Basit without translation) from here.


Treatment Plan

Just Listen to it three times a day (morning, afternoon, evening) for seven consecutive days using following procedure:-


    Before listening:

  • Close your eyes
  • Feel your self in front of ALLAH Almighty/ God
  • Then listen to it with greater concentration and closed eyes

    When the recitation/ AUDIO is finished:

  • Open your eyes and take half glass of water
  • Close your eyes again and say “ALLAH” three times in your heart with deep affection/ love
  • Then drink the water with closed eyes in three sips

Surah Al-Rehman – The Ultimate Free Remedy for Incurable Diseases

(By Listening Only- 20 Minutes Only)

Kindly download the Surah “AL-REHMAN” (recited by Qari Abdul Basit without translation) from here.


Treatment Plan

Just Listen to it three times a day (morning, afternoon, evening) for seven consecutive days using following procedure:-


    Before listening:

  • Close your eyes
  • Feel your self in front of ALLAH Almighty/ God
  • Then listen to it with greater concentration and closed eyes

    When the recitation/ AUDIO is finished:

  • Open your eyes and take half glass of water
  • Close your eyes again and say “ALLAH” three times in your heart with deep affection/ love
  • Then drink the water with closed eyes in three sips